Abstract:ABSTRACTThe present study determined the effect of the tumor‐targeting strain Salmonella typhimurium A1‐R (S. typhimurium A1‐R) on CD8+ tumor‐infiltrating lymphocytes (TILs) in a syngeneic pancreatic‐cancer orthotopic mouse model. The effect of tumor‐targeting S. typhimurium A1‐R on CD8+ TILs was determined on the Pan02 murine pancreatic‐adenocarcinoma implanted orthotopically in the pancreatic tail of C57BL/6 immunocompromised mice. Three weeks after orthotopic implantation, mice were randomized as follows G1: untreated control group (n = 8); and G2: S. typhimurium A1‐R‐treatment group (n = 8, 1 × 107 colony forming units [CFU]/body, iv, weekly, 3 weeks). On the 22nd day from initial treatment, all mice were sacrificed and tumors were harvested. The tumor‐volume ratio was defined as ratio of tumor volume on the 22nd day relative to the 1st day. The tumor volume ratio was significantly lower in the S. typhimurium A1‐R‐treated group (G2) (3.0 ± 2.8) than the untreated control (G1) (39.9 ± 30.7, P < 0.01). Hematoxylin and easin (H&E) staining on tumor sections was performed to evaluate tumor destruction which was classified according to the Evans grading system and found to be much greater in the S. typhimurium A1‐R‐treated mice (G2). Six mice in G1 had peritoneal dissemination, whereas no mice showed peritoneal dissemination in G2 (P < 0.01). Immunohistochemical staining with anti‐mouse CD8+ antibody was performed in order to detect TILs determined by calculating the average number of CD8+ cells in three high power fields (200×) in the treated and untreated tumors. The TIL score was significantly higher in G2 (133.5 ± 32.2) than G1 (45.1 ± 19.4, P < 0.001). The present study demonstrates that S. typhimurium A1‐R promotes CD8+ T cell infiltration and inhibition of tumor growth and metastasis. J. Cell. Biochem. 119: 634–639, 2018. © 2017 Wiley Periodicals, Inc.

Genetically Targeted T Cells Eradicate Established Breast Cancer in Syngeneic Mice.

Genetically engineered T cells for cancer immunotherapy

Specific Growth Inhibition of ErbB2‑expressing Human Breast Cancer Cells by Genetically Modified NK‑92 Cells

DC Targeting DNA Vaccines Induce Protective and Therapeutic Antitumor Immunity in Mice.

Cancer Immunotherapy Using in Vitro Genetically Modified Targeted Dendritic Cells

Targeted Delivery of Tumor Antigens to Activated Dendritic Cells Via CD11c Molecules Induces Potent Antitumor Immunity in Mice

Cell therapy of a highly invasive human breast carcinoma implanted in immunodeficient (SCID) mice

Tumor-Targeting Salmonella Typhimurium A1-R in Combination with Trastuzumab Eradicates HER-2-Positive Cervical Cancer Cells in Patient-Derived Mouse Models

Long-lasting complete regression of established mouse tumors by counteracting Th2 inflammation.

Engineering T Cells to Express Tumoricidal MDA-7/IL24 Enhances Cancer Immunotherapy

T Cells Expressing a HER2-specific Chimeric Antigen Receptor As Treatment for Breast Cancer.

Adoptive Transfer Of Tumor-Reactive Transforming Growth Factor-Beta-Insensitive Cd8(+) T Cells: Eradication Of Autologous Mouse Prostate Cancer

A Humanized Mouse Model for Generation of Tumor Antigen Specific T Cells for Preclinical Research and Anticancer Therapy (75.4)

Specific Targeted Killing of ErbB2 Positive Breast Cancer by Retro Virus-Mediated Immunocaspase-3 Secreting T Cells

Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy

Tumor‐Targeting Salmonella Typhimurium A1‐R Promotes Tumoricidal CD8+ T Cell Tumor Infiltration and Arrests Growth and Metastasis in a Syngeneic Pancreatic‐Cancer Orthotopic Mouse Model

Antibody-mediated targeting of TNFR2 activates CD8 + T cells in mice and promotes antitumor immunity.

Generation of Human T Cells Expressing Only the Engineered Tumor Antigen Specific TCR in Humanized Mice for Preclinical Research and Anticancer Therapy (P4364)

A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells

Antitumor Activity from Antigen-Specific CD8 T Cells Generated in Vivo from Genetically Engineered Human Hematopoietic Stem Cells

Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells.